Boehringer Ingelheim Joins The Corporate Venture Party
This article was originally published in Start Up
Executive SummaryIn late March, Boehringer Ingelheim GMBH formally unveiled its $134 million corporate venture fund, a strategically-focused effort that will invest in areas believed to be important to the privately-held German pharma's future growth, including RNA silencing, stem cells, and next generation vaccine, protein, and antibody technologies.
You may also be interested in...
Germany's Boehringer Ingelheim returns to sales growth and looks to Phase III hepatitis C and oncology products to provide long-term growth.